{'52WeekChange': -0.30527568,
 'SandP52WeekChange': 0.0644362,
 'address1': '55 Cambridge Parkway',
 'address2': 'Suite 901 East',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 13.8,
 'askSize': 1300,
 'averageDailyVolume10Day': 91037,
 'averageVolume': 135069,
 'averageVolume10days': 91037,
 'beta': 2.404352,
 'beta3Year': None,
 'bid': 6.55,
 'bidSize': 21500,
 'bookValue': 4.693,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.41,
 'dayLow': 11.69,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.576,
 'enterpriseToRevenue': 11.277,
 'enterpriseValue': 143100464,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '866-553-3269',
 'fiftyDayAverage': 11.735286,
 'fiftyTwoWeekHigh': 18.96,
 'fiftyTwoWeekLow': 5.605,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 11061531,
 'forwardEps': -2.79,
 'forwardPE': -4.200717,
 'fromCurrency': None,
 'fullTimeEmployees': 56,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.09571999,
 'heldPercentInstitutions': 0.94474,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1588204800,
 'lastMarket': None,
 'lastSplitDate': 1479772800,
 'lastSplitFactor': '1:14',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/kalvista.com',
 'longBusinessSummary': 'KalVista Pharmaceuticals, Inc., a clinical stage '
                        'pharmaceutical company, discovers, develops, and '
                        'commercializes small molecule protease inhibitors for '
                        "diseases with unmet needs. The company's product "
                        'portfolio comprises small molecule plasma kallikrein '
                        'inhibitors targeting hereditary angioedema (HAE) and '
                        'diabetic macular edema (DME); and oral plasma '
                        'kallikrein inhibitors. Its products include KVD001, a '
                        'plasma kallikrein inhibitor that completed a Phase II '
                        'clinical trial for the treatment of DME; KVD900, '
                        'which is in Phase II clinical trial for treating HAE '
                        'attacks; and KVD824, an oral plasma kallikrein '
                        'inhibitor that completed a Phase I clinical trial for '
                        'treating DME or HAE. The company is headquartered in '
                        'Cambridge, Massachusetts.',
 'longName': 'KalVista Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 209169184,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_136678928',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1588204800,
 'navPrice': None,
 'netIncomeToCommon': -29116000,
 'nextFiscalYearEnd': 1651276800,
 'open': 12.41,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '857-999-0075',
 'previousClose': 12.54,
 'priceHint': 2,
 'priceToBook': 2.4973366,
 'priceToSalesTrailing12Months': 16.482994,
 'profitMargins': -2.2944,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.41,
 'regularMarketDayLow': 11.69,
 'regularMarketOpen': 12.41,
 'regularMarketPreviousClose': 12.54,
 'regularMarketPrice': 12.41,
 'regularMarketVolume': 62907,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 17845600,
 'sharesPercentSharesOut': 0.022,
 'sharesShort': 391842,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 341171,
 'shortName': 'KalVista Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0312,
 'shortRatio': 2.03,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'KALV',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.64,
 'twoHundredDayAverage': 11.958885,
 'volume': 62907,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.kalvista.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02142'}